Pulmonary Flashcards
(30 cards)
Pathophys of ARDS
Injury causes capillary leak, protein leaves vascular space leading to interstitial and alveolar flooding. This all causes gas exchange abnormalities, decreased lung compliance and elevated PVR/pulm HTN
Berlin definition of ARDS
1) less than 1 week of clinical insult
2) bilateral infiltrates not explained by effusion, atelectasis or nodules
3) edema not fully cardiac in etiology
4) PEEP greater than 5
5) P/F <300
Prone positioning
Improves survival in severe ARDS P/F<150. Prone for 16 hours after trying to stabilize for 12-24 hours
Steroids in ARDS
Improves survival in early mod-severe ARDS
Avoid in flu and late ARDS (week 2-3 of ARDS)
Obesity and intubation
Decreased FRC leads to early desaturation after induction
MACOCHA Score
Analyzes difficult airways
Induction Agents
Propofol: best but causes hypotension. Onset 9-50 sec, lasts for 3-10 min. Dose 0.5-2 mg/kg
Etomidate: reduced adrenal steroidogenesis. Onset 30-60 sec, lasts for 3-5 min. Dose 0.15-0.3 mg/kg
Ketamine: reduced pressor response. Onset 60-120sec, lasts for 5-15 min. Dose 2 mg/kg
Neuromuscular Blockade (RSI)
Succinylcholine: onset 30-60 sec, lasts 5-15 min. Dose 1-1.5 mg/kg.
Contraindications: hx of malignant hyperthermia, hyperkalemia, UMN and LMN lesions, myopathy, crush injury, severe burns, prolonged immobility
Rocuronium: onset 45-60 sec, lasts for 45-70 min. Dose 0.8-1.2 mg/kg
Sugammadex is reversal agent. 16 mg/kg
Planning intubation success
Upper lip bite test: asses jaw movement
MACOCHA
preoxygenate
Videolaryngoscopy
Tracheostomy indications
Difficult airway, prolonged MV: allows for oral hygiene, resp secretion clearance, early mobilization, conditioning
Facilitates vent liberation: decreases artificial airway resistance and anatomical dead space
Percutaneous trach
Advantages: bedside, rapid and less $$, lower EBL and infection
Disadvantages: tracheal lac, esophageal perf
Contraindications: unstable c-spine, ambiguous surface anatomy, difficult airway
Trach complications
Dislodgement: <7 days: fiber optic replacement with orotracheal intubation to stabilize. If >7d then reinsert
Obstruction: removed inner cannula
Tracheitis/stomal infection
Tracheomalacia
Trach bleeding
Early: >7d. Surgical site bleeding
Late: granulation tissue, stomal infection, erosion of thyroid vessels, tracheal wall erosion or tracheoinnominate fistula
Tracheal cuff pressure
Keep <15 mm Hg to prevent ischemic injury
Bromchoscopy indications in ICU
Airway management
VAP
Hemoptysis
Symptomatic atelectasis/central obstruction
Aspirated foreign body
Massive Hemoptysis
Mortality 13-17.8%
Due to TB, mycetoma, bronchiectasis, cancer and iatrogenic
Bronchial Artery Embolization
Immediate success in 70-90%
Recurrence up to 58% in 30d
Surgery is effective in localized disease but otherwise high mortality in emergency setting (50%)
Management of tracheal obstruction
Tracheostomy or resection for local dz
Emergent rigid bronch to reesrablish airway —> balloon dilate and stent
Fiberoptic flex bronch risks bleeding and airway compromise
Negative pressure pulmonary edema
Young, developed larygospasm during anesthesia that results in edema and resp failure. Large pressure swings against a closed epiglottis
Post extubation stridor risk factors
Traumatic intubation
Intubation >6d
Large ETT
Female gender
Reintubation after unplanned extubation
Physiology of obstructive resp failure
Increased airway resistance: inflammation, edema, smooth muscle tone, mucous
Increased WOB: increased CO2 (fever) and subsequent minute ventilation. Hyperinflation that increases dead space ventilation, inspiratoey threshold load and WOB
Inspiratory threshold load
Must overcome intrinsic PEEP (autopeep) to inhale
Negative pressure required to initiate flow = inspirstory threshold load
For normal person: alveolar pressure needs to be slightly less than 0 to initiate flow. In hyperinflation, alveolar pressure may be high (18) and so alveolar pressure must decrease by >18 to initiate flow
Inhaled beta adrenergic agonists
Albuterol, levalalbuterol
Short acting and quick onset
Given via nebular or MDI (no benefit to nebulized)
No benefit to increasing dose or continuous
Inhaled anticholingergics (ipratropium)
Short acting
COPD: evidence for efficacy is conflicting
Asthma: increased bronchodilation compared to b agonists alone